Avadel Pharmaceuticals plc
AVDL
$14.20
$0.201.43%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 221.08M | 194.45M | 169.12M | 138.16M | 95.15M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 221.08M | 194.45M | 169.12M | 138.16M | 95.15M |
| Cost of Revenue | 22.91M | 19.33M | 15.28M | 11.16M | 5.12M |
| Gross Profit | 198.17M | 175.12M | 153.84M | 127.00M | 90.03M |
| SG&A Expenses | 179.22M | 178.00M | 181.04M | 177.72M | 176.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 218.82M | 213.82M | 211.52M | 202.16M | 193.94M |
| Operating Income | 2.26M | -19.37M | -42.40M | -64.00M | -98.79M |
| Income Before Tax | -5.85M | -26.67M | -49.08M | -73.00M | -106.65M |
| Income Tax Expenses | -2.92M | -263.00K | -248.00K | -428.00K | -427.00K |
| Earnings from Continuing Operations | -2.92 | -26.41 | -48.83 | -72.58 | -106.22 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.92M | -26.41M | -48.83M | -72.58M | -106.22M |
| EBIT | 2.26M | -19.37M | -42.40M | -64.00M | -98.79M |
| EBITDA | 5.86M | -16.40M | -39.72M | -61.55M | -96.77M |
| EPS Basic | -0.03 | -0.27 | -0.52 | -0.79 | -1.17 |
| Normalized Basic EPS | -0.04 | -0.18 | -0.34 | -0.49 | -0.73 |
| EPS Diluted | -0.03 | -0.28 | -0.53 | -0.79 | -1.17 |
| Normalized Diluted EPS | -0.04 | -0.18 | -0.34 | -0.49 | -0.73 |
| Average Basic Shares Outstanding | 386.02M | 385.45M | 380.54M | 374.05M | 367.13M |
| Average Diluted Shares Outstanding | 388.38M | 385.45M | 380.54M | 374.05M | 367.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |